INBS — Intelligent Bio Solutions Inc.
NASDAQ · Healthcare · Medical Devices
$2.40
-$0.03 (-1.23%)
Intelligent Bio Solutions Inc. (INBS) is a medical devices company listed on NASDAQ. It is led by Harry Simeonidis, based in 135 West, 41st Street, New York, NY, United States, 10036, with about 53 employees. Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.
Latest reported INBS revenue for 2026-06-30 was $4.2M. Net income was -$12.4M. Revenue was up 37.3% from 2026-03-31 to 2026-06-30. INBS currently screens at market cap $5.9M.
Use this INBS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the INBS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the INBS SEC filings page. Lician reads the product cache first so this HTML stays unique to Intelligent Bio Solutions Inc. even when a live quote feed is slow.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.
INBS Key Statistics
Market Cap
$5.86M
Volume
207,272
Previous Close
$2.51
Day Range
$2.25 – $2.67
EPS
-$8.44
Revenue
$4.22M
Net Income
-$12.43M
Gross Profit
$2.05M
Free Cash Flow
-$11.80M
Revenue Growth
+38.1%
Profit Margin
-294.9%
Debt to Equity
0.00
Employees
53
INBS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2026 | FY2025 |
|---|---|---|
| Revenue | $4.22M | $3.05M |
| Cost of Revenue | $2.17M | $1.81M |
| Gross Profit | $2.05M | $1.25M |
| Operating Income | -$12.61M | -$10.64M |
| Net Income | -$12.43M | -$10.57M |
| EPS (Diluted) | -$8.44 | -$2.00 |
Total Assets
$11.94M
Total Debt
$0.00
Shareholders' Equity
$5.51M
Cash & Equivalents
$3.99M
Operating Cash Flow
-$11.93M
Free Cash Flow
-$11.80M
Intelligent Bio Solutions Inc. Company Information
- President & CEO
- Harry Simeonidis
- Headquarters
- 135 West, 41st Street, New York, NY, United States, 10036
- Website
- ibs.inc
- Phone
- 646 828 8258
- IPO / Founded
- 2020-12-23
- Sector
- Healthcare
- Industry
- Medical Devices